drugset / Trial / NCT00318903
Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer
Phase 2
Completed
25 enrolled
University of Alabama at Birmingham
Aventis Pharmaceuticals · collabPharmacia and Upjohn · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
There is a need for more effective therapy for patients following surgery for esophageal carcinoma. Docetaxel and Irinotecan, independent of each other, have demonstrated activity in this disease. There is interest in the combination of these two active agents plus radiotherapy.
Timeline
- Start
- 2002-01
- Primary completion
- —
- Completion
- 2006-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 25 mg/m2 | Intravenous |
| Subject | Irinotecan | Small molecule | 45 mg/m2 | Intravenous |